{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T19:57:16Z","timestamp":1792612636993,"version":"4.5.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T00:00:00Z","timestamp":1739836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T00:00:00Z","timestamp":1739836800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Chemo-immunotherapy is the current first-line treatment for patients with extensive-stage small cell lung cancer (ES-SCLC), but survival benefits are modest. We aimed to evaluate the safety, antitumor activity and biomarkers of first-line camrelizumab and apatinib plus chemotherapy in untreated ES-SCLC patients. In this single-arm trial (ClinicalTrials.gov NCT05001412), eligible patients received 2 cycles of etoposide and carboplatin (EC) as induction treatment followed by 2\u20134 cycles of camrelizumab, apatinib plus EC, then maintenance camrelizumab plus apatinib. Primary endpoint was safety. Secondary endpoints included objective response rate (ORR), duration of response, progression-free survival (PFS), and overall survival (OS). Targeted sequencing and whole transcriptome sequencing were performed to explore biomarkers. All enrolled 40 patients were treated and analyzed for safety. During the entire treatment, treatment-emergent adverse events (TEAEs) occurred in 40 patients (100%), and 30 (75.0%) were grade \u22653. The most common grade \u22653 TEAEs were neutropenia (35.0%), anemia (15.0%) and increased alanine aminotransferase (15.0%). No treatment-related deaths occurred. Among 36 evaluable patients, ORR was 88.9% (95% CI: 73.9%\u201396.9%), median PFS was 7.3 months (95% CI: 6.6\u20139.2) and median OS was 17.3 months (11.8-not reached). Mutations in RB1, high levels of tumor mutation burden, natural killer cells, and interferons, and low levels of cancer-associated fibroblasts, correlated with prolonged PFS. Induction chemotherapy followed by camrelizumab, apatinib plus EC demonstrated acceptable safety and promising antitumor activity in untreated ES-SCLC patients. The identified biomarkers need further validation.<\/jats:p>\n          <jats:p>\n            <jats:bold>Trial Registration<\/jats:bold> ClinicalTrials.gov Identifier: NCT05001412.<\/jats:p>","DOI":"10.1038\/s41392-025-02153-7","type":"journal-article","created":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T23:04:24Z","timestamp":1739833464000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Induction chemotherapy followed by camrelizumab plus apatinib and chemotherapy as first-line treatment for extensive-stage small-cell lung cancer: a multicenter, single-arm trial"],"prefix":"10.1038","volume":"10","author":[{"given":"Ming","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guihuan","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhui","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinqing","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanhong","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiexia","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinyin","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haijian","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2515-5589","authenticated-orcid":false,"given":"Nanshan","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengzhi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,18]]},"reference":[{"key":"2153_CR1","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.jtho.2015.10.008","volume":"11","author":"AG Nicholson","year":"2016","unstructured":"Nicholson, A. G. et al. The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revision of the Clinical and Pathologic Staging of Small Cell Lung Cancer in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. J. Thorac. Oncol. 11, 300\u2013311 (2016).","journal-title":"J. Thorac. Oncol."},{"key":"2153_CR2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41572-020-00235-0","volume":"7","author":"CM Rudin","year":"2021","unstructured":"Rudin, C. M., Brambilla, E., Faivre-Finn, C. & Sage, J. Small-cell lung cancer. Nat. Rev. Dis. Prim. 7, 3 (2021).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"2153_CR3","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.lungcan.2011.08.004","volume":"75","author":"SP Riaz","year":"2012","unstructured":"Riaz, S. P. et al. Trends in incidence of small cell lung cancer and all lung cancer. Lung Cancer 75, 280\u2013284 (2012).","journal-title":"Lung Cancer"},{"key":"2153_CR4","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","volume":"379","author":"L Horn","year":"2018","unstructured":"Horn, L. et al. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. N. Engl. J. Med 379, 2220\u20132229 (2018).","journal-title":"N. Engl. J. Med"},{"key":"2153_CR5","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","volume":"394","author":"L Paz-Ares","year":"2019","unstructured":"Paz-Ares, L. et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet 394, 1929\u20131939 (2019).","journal-title":"Lancet"},{"key":"2153_CR6","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1200\/JCO.20.01055","volume":"39","author":"SV Liu","year":"2021","unstructured":"Liu, S. V. et al. Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133). J. Clin. Oncol. 39, 619\u2013630 (2021).","journal-title":"J. Clin. Oncol."},{"key":"2153_CR7","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1001\/jama.2022.16464","volume":"328","author":"Y Cheng","year":"2022","unstructured":"Cheng, Y. et al. Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer: The ASTRUM-005 Randomized Clinical Trial. Jama 328, 1223\u20131232 (2022).","journal-title":"Jama"},{"key":"2153_CR8","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S1470-2045(22)00224-8","volume":"23","author":"J Wang","year":"2022","unstructured":"Wang, J. et al. Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 23, 739\u2013747 (2022).","journal-title":"Lancet Oncol."},{"key":"2153_CR9","doi-asserted-by":"crossref","first-page":"102606","DOI":"10.1016\/j.ctrv.2023.102606","volume":"120","author":"Y Chen","year":"2023","unstructured":"Chen, Y., Li, H. & Fan, Y. Shaping the tumor immune microenvironment of SCLC: Mechanisms, and opportunities for immunotherapy. Cancer Treat. Rev. 120, 102606 (2023).","journal-title":"Cancer Treat. Rev."},{"key":"2153_CR10","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646\u2013674 (2011).","journal-title":"Cell"},{"key":"2153_CR11","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/S1010-7940(02)00112-4","volume":"21","author":"M Lucchi","year":"2002","unstructured":"Lucchi, M. et al. Small cell lung carcinoma (SCLC): the angiogenic phenomenon. Eur. J. Cardiothorac. Surg. 21, 1105\u20131110 (2002).","journal-title":"Eur. J. Cardiothorac. Surg."},{"key":"2153_CR12","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/s41571-021-00496-y","volume":"18","author":"ZR Huinen","year":"2021","unstructured":"Huinen, Z. R., Huijbers, E. J. M., van Beijnum, J. R., Nowak-Sliwinska, P. & Griffioen, A. W. Anti-angiogenic agents - overcoming tumour endothelial cell anergy and improving immunotherapy outcomes. Nat. Rev. Clin. Oncol. 18, 527\u2013540 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2153_CR13","doi-asserted-by":"crossref","first-page":"4270","DOI":"10.1158\/0008-5472.CAN-17-2176","volume":"78","author":"L Meder","year":"2018","unstructured":"Meder, L. et al. Combined VEGF and PD-L1 Blockade Displays Synergistic Treatment Effects in an Autochthonous Mouse Model of Small Cell Lung Cancer. Cancer Res 78, 4270\u20134281 (2018).","journal-title":"Cancer Res"},{"key":"2153_CR14","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1158\/2326-6066.CIR-17-0640","volume":"7","author":"S Zhao","year":"2019","unstructured":"Zhao, S. et al. Low-Dose Apatinib Optimizes Tumor Microenvironment and Potentiates Antitumor Effect of PD-1\/PD-L1 Blockade in Lung Cancer. Cancer Immunol. Res 7, 630\u2013643 (2019).","journal-title":"Cancer Immunol. Res"},{"key":"2153_CR15","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","volume":"378","author":"MA Socinski","year":"2018","unstructured":"Socinski, M. A. et al. Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. N. Engl. J. Med 378, 2288\u20132301 (2018).","journal-title":"N. Engl. J. Med"},{"key":"2153_CR16","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1200\/JCO.2016.69.4844","volume":"35","author":"M Tiseo","year":"2017","unstructured":"Tiseo, M. et al. Italian, multicenter, phase III, randomized study of cisplatin plus etoposide with or without bevacizumab as first-line treatment in extensive-disease small-cell lung cancer: the GOIRC-AIFA FARM6PMFJM trial. J. Clin. Oncol. 35, 1281\u20131287 (2017).","journal-title":"J. Clin. Oncol."},{"key":"2153_CR17","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1038\/s41591-024-03132-1","volume":"30","author":"Y Cheng","year":"2024","unstructured":"Cheng, Y. et al. Benmelstobart, anlotinib and chemotherapy in extensive-stage small-cell lung cancer: a randomized phase 3 trial. Nat. Med 30, 2967\u20132976 (2024).","journal-title":"Nat. Med"},{"key":"2153_CR18","doi-asserted-by":"crossref","first-page":"abstr. e20107","DOI":"10.1200\/JCO.2024.42.16_suppl.e20107","volume":"42","author":"Y Zhao","year":"2024","unstructured":"Zhao, Y. et al. Camrelizumab combined with chemotherapy followed by maintenance camrelizumab and apatinib as first-line therapy for extensive-stage small cell lung cancer: A phase II, single-arm, exploratory study. J. Clin. Oncol. 42, abstr. e20107\u2013e20107 (2024).","journal-title":"J. Clin. Oncol."},{"key":"2153_CR19","doi-asserted-by":"crossref","first-page":"1180735","DOI":"10.3389\/fonc.2023.1180735","volume":"13","author":"J Tian","year":"2023","unstructured":"Tian, J., Sui, L., Wang, H. & Chen, X. Camrelizumab as a novel third or post-third-line treatment strategy in small cell lung cancer: a retrospective study of 12 patients. Front Oncol. 13, 1180735 (2023).","journal-title":"Front Oncol."},{"key":"2153_CR20","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/s41416-019-0583-6","volume":"121","author":"Y Xu","year":"2019","unstructured":"Xu, Y. et al. Apatinib in patients with extensive-stage small-cell lung cancer after second-line or third-line chemotherapy: a phase II, single-arm, multicentre, prospective study. Br. J. Cancer 121, 640\u2013646 (2019).","journal-title":"Br. J. Cancer"},{"key":"2153_CR21","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.jtho.2020.10.002","volume":"16","author":"Y Fan","year":"2021","unstructured":"Fan, Y. et al. Camrelizumab Plus Apatinib in Extensive-Stage SCLC (PASSION): A Multicenter, Two-Stage, Phase 2 Trial. J. Thorac. Oncol. 16, 299\u2013309 (2021).","journal-title":"J. Thorac. Oncol."},{"key":"2153_CR22","doi-asserted-by":"crossref","first-page":"1168879","DOI":"10.3389\/fimmu.2023.1168879","volume":"14","author":"J Ni","year":"2023","unstructured":"Ni, J., Si, X., Wang, H., Zhang, X. & Zhang, L. Camrelizumab plus platinum-irinotecan followed by maintenance camrelizumab plus apatinib in untreated extensive-stage small-cell lung cancer: a nonrandomized clinical trial. Front Immunol. 14, 1168879 (2023).","journal-title":"Front Immunol."},{"key":"2153_CR23","doi-asserted-by":"crossref","first-page":"3488","DOI":"10.1200\/JCO.2005.01.082","volume":"23","author":"JY Han","year":"2005","unstructured":"Han, J. Y. et al. Phase II study of irinotecan plus cisplatin induction followed by concurrent twice-daily thoracic irradiation with etoposide plus cisplatin chemotherapy for limited-disease small-cell lung cancer. J. Clin. Oncol. 23, 3488\u20133494 (2005).","journal-title":"J. Clin. Oncol."},{"key":"2153_CR24","volume":"9","author":"Z Li","year":"2022","unstructured":"Li, Z. et al. Immunogenic Cell Death Activates the Tumor Immune Microenvironment to Boost the Immunotherapy Efficiency. Adv. Sci. (Weinh.) 9, e2201734 (2022).","journal-title":"Adv. Sci. (Weinh.)"},{"key":"2153_CR25","unstructured":"Guidelines of Chinese Society of Clinical Oncology (CSCO) for Small-Cell Lung Cancer (2020 version)."},{"key":"2153_CR26","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/s41392-023-01460-1","volume":"8","author":"ZL Liu","year":"2023","unstructured":"Liu, Z. L., Chen, H. H., Zheng, L. L., Sun, L. P. & Shi, L. Angiogenic signaling pathways and anti-angiogenic therapy for cancer. Signal Transduct. Target Ther. 8, 198 (2023).","journal-title":"Signal Transduct. Target Ther."},{"key":"2153_CR27","volume":"10","author":"D Zhang","year":"2024","unstructured":"Zhang, D. et al. Clinical efficacy of Camrelizumab combined with first-line chemotherapy in extensive-stage small-cell lung cancer. Heliyon 10, e22913 (2024).","journal-title":"Heliyon"},{"key":"2153_CR28","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1002\/cac2.12119","volume":"40","author":"B Zhang","year":"2020","unstructured":"Zhang, B. et al. Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first-line treatment of advanced esophageal squamous cell carcinoma. Cancer Commun. (Lond.) 40, 711\u2013720 (2020).","journal-title":"Cancer Commun. (Lond.)"},{"key":"2153_CR29","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41392-024-01773-9","volume":"9","author":"X Chen","year":"2024","unstructured":"Chen, X. et al. First-line camrelizumab (a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and chemotherapy for advanced gastric cancer (SPACE): a phase 1 study. Signal Transduct. Target Ther. 9, 73 (2024).","journal-title":"Signal Transduct. Target Ther."},{"key":"2153_CR30","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/s41392-024-01957-3","volume":"9","author":"X Han","year":"2024","unstructured":"Han, X. et al. Sintilimab combined with anlotinib and chemotherapy as second-line or later therapy in extensive-stage small cell lung cancer: a phase II clinical trial. Signal Transduct. Target Ther. 9, 241 (2024).","journal-title":"Signal Transduct. Target Ther."},{"key":"2153_CR31","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41392-024-01974-2","volume":"9","author":"Y Zhang","year":"2024","unstructured":"Zhang, Y. et al. Surufatinib plus toripalimab combined with etoposide and cisplatin as first-line treatment in advanced small-cell lung cancer patients: a phase Ib\/II trial. Signal Transduct. Target Ther. 9, 255 (2024).","journal-title":"Signal Transduct. Target Ther."},{"key":"2153_CR32","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1038\/s12276-020-00500-y","volume":"52","author":"WS Lee","year":"2020","unstructured":"Lee, W. S., Yang, H., Chon, H. J. & Kim, C. Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity. Exp. Mol. Med 52, 1475\u20131485 (2020).","journal-title":"Exp. Mol. Med"},{"key":"2153_CR33","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.3390\/cells9112393","volume":"9","author":"E Acheampong","year":"2020","unstructured":"Acheampong, E. et al. Tumour PD-L1 Expression in Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. Cells 9, 2393 (2020).","journal-title":"Cells"},{"key":"2153_CR34","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1158\/2159-8290.CD-22-0620","volume":"13","author":"S Sivakumar","year":"2023","unstructured":"Sivakumar, S. et al. Integrative Analysis of a Large Real-World Cohort of Small Cell Lung Cancer Identifies Distinct Genetic Subtypes and Insights into Histologic Transformation. Cancer Discov. 13, 1572\u20131591 (2023).","journal-title":"Cancer Discov."},{"key":"2153_CR35","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s40425-019-0572-6","volume":"7","author":"B Ricciuti","year":"2019","unstructured":"Ricciuti, B. et al. Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer. J. Immunother. Cancer 7, 87 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"2153_CR36","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.ccell.2018.04.001","volume":"33","author":"MD Hellmann","year":"2018","unstructured":"Hellmann, M. D. et al. Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer. Cancer Cell 33, 853\u2013861.e854 (2018).","journal-title":"Cancer Cell"},{"key":"2153_CR37","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1007\/s12094-024-03479-4","volume":"26","author":"Y Cui","year":"2024","unstructured":"Cui, Y. et al. Peripheral NK cells identified as the predictor of response in extensive-stage small cell lung cancer patients treated with first-line immunotherapy plus chemotherapy. Clin. Transl. Oncol. 26, 2522\u20132530 (2024).","journal-title":"Clin. Transl. Oncol."},{"key":"2153_CR38","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1200\/JCO.22.00727","volume":"41","author":"Z Wang","year":"2023","unstructured":"Wang, Z. et al. Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non-Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01). J. Clin. Oncol. 41, 651\u2013663 (2023).","journal-title":"J. Clin. Oncol."},{"key":"2153_CR39","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/j.ccell.2024.08.013","volume":"42","author":"J Xu","year":"2024","unstructured":"Xu, J. et al. Circulating tumor DNA-based stratification strategy for chemotherapy plus PD-1 inhibitor in advanced non-small-cell lung cancer. Cancer Cell 42, 1598\u20131613.e1594 (2024).","journal-title":"Cancer Cell"},{"key":"2153_CR40","volume":"20","author":"G Zhang","year":"2022","unstructured":"Zhang, G. et al. Distinct clinical and somatic mutational features of breast tumors with high-, low-, or non-expressing human epidermal growth factor receptor 2 status. BMC Med. 20, 142 (2022).","journal-title":"BMC Med."},{"key":"2153_CR41","volume":"7","author":"J Feng","year":"2023","unstructured":"Feng, J. et al. Combination of genomic instability score and TP53 status for prognosis prediction in lung adenocarcinoma. NPJ Precis Oncol. 7, 110 (2023).","journal-title":"NPJ Precis Oncol."},{"key":"2153_CR42","doi-asserted-by":"crossref","first-page":"e010041","DOI":"10.1136\/jitc-2024-010041","volume":"12","author":"Z Ji","year":"2024","unstructured":"Ji, Z. et al. Multiomics reveals tumor microenvironment remodeling in locally advanced gastric andgastroesophageal junction cancer following neoadjuvant immunotherapy and chemotherapy. J. Immunother. Cancer 12, e010041 (2024).","journal-title":"J. Immunother. Cancer"},{"key":"2153_CR43","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.ccell.2021.04.014","volume":"39","author":"A Bagaev","year":"2021","unstructured":"Bagaev, A. et al. Conserved pan-cancer microenvironment subtypes predict response to immunotherapy. Cancer Cell 39, 845\u2013865.e847 (2021).","journal-title":"Cancer Cell"},{"key":"2153_CR44","doi-asserted-by":"crossref","first-page":"bbaa311","DOI":"10.1093\/bib\/bbaa311","volume":"22","author":"S Wang","year":"2021","unstructured":"Wang, S. et al. Clinical significance and immunogenomic landscape analyses of the immune cell signature based prognostic model for patients with breast cancer. Brief Bioinform. 22, bbaa311 (2021).","journal-title":"Brief Bioinform."},{"key":"2153_CR45","volume":"9","author":"Q Jia","year":"2018","unstructured":"Jia, Q. et al. Local mutational diversity drives intratumoral immune heterogeneity in non-small cell lung cancer. Nat. Commun. 9, 5361 (2018).","journal-title":"Nat. Commun."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02153-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02153-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02153-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T23:04:37Z","timestamp":1739833477000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02153-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,18]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2153"],"URL":"https:\/\/doi.org\/10.1038\/s41392-025-02153-7","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,18]]},"assertion":[{"value":"12 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"65"}}